Verbasnol (Verbascoside)

Verbascoside (also called acteoside) is a phenylethanoid glycoside found in Verbascum, Olea europaea, and numerous medicinal herbs, exerting its primary effects through free radical scavenging and modulation of inflammatory enzyme expression. Its antioxidant and anti-inflammatory mechanisms involve direct ROS neutralization, AMPK pathway regulation, and suppression of inducible nitric oxide synthase (iNOS) activity.

Origin & History

Verbasnol (verbascoside) is a water-soluble phenylethanoid glycoside found in over 220 plant species, including mullein (Verbascum species), Lippia citriodora, and Plantago lanceolata. It was first isolated from mullein and is typically obtained through standard herbal extraction processes, often standardized to ≥5% in proprietary extracts.

Historical & Cultural Context

Verbascoside is found in medicinal plants used in traditional Chinese medicine and other herbal systems, valued for antioxidative, antineoplastic, anti-inflammatory, antimicrobial, and neuroprotective effects. It contributes to the holistic management of chronic diseases in traditional contexts, though specific historical durations or indications are not detailed.

Health Benefits

• Antioxidant protection: Scavenges reactive oxygen species and inhibits liver fibrosis via AMPK pathway downregulation (preclinical evidence)
• Anti-inflammatory effects: Reduces iNOS expression and superoxide production in inflammatory cells (in vitro studies)
• Neuroprotection: Systematic review of 32 preclinical trials supports neuroprotective and antidepressant effects
• Platelet function: One human study showed 100mg daily for 2 weeks significantly decreased platelet aggregation
• Cellular protection: Protects pancreatic β-cells from ER stress and improves insulin content (in vitro evidence)

How It Works

Verbascoside scavenges reactive oxygen species including superoxide anion and hydroxyl radicals by donating hydrogen atoms from its catechol moiety, reducing oxidative cellular damage. It suppresses inducible nitric oxide synthase (iNOS) expression and inhibits superoxide production in activated macrophages, limiting nitrosative stress in inflamed tissue. In hepatic fibrosis models, verbascoside downregulates the AMPK signaling pathway, attenuating stellate cell activation and collagen deposition at the preclinical level.

Scientific Research

Clinical evidence for verbascoside is limited, with only one human study reporting that 100mg oral verbascoside for 2 weeks significantly decreased platelet aggregation. A systematic review of 32 preclinical trials (up to April 2023) supports neuroprotective effects but calls for multicenter clinical studies. Most evidence comes from in vitro and animal models showing doses up to 5000mg/kg with no acute toxicity.

Clinical Summary

The bulk of verbascoside research consists of in vitro cell studies and animal models rather than randomized controlled human trials, limiting direct clinical translation. Preclinical studies in rodent liver fibrosis models demonstrate measurable reductions in fibrotic markers via AMPK pathway inhibition, while in vitro inflammatory models show dose-dependent suppression of iNOS and superoxide in macrophage cell lines. A systematic review has examined verbascoside's neuroprotective potential, consolidating preclinical findings but noting the absence of adequately powered human trials. Overall, the current evidence base is promising but insufficient to establish clinical efficacy, recommended dosages, or therapeutic endpoints in humans.

Nutritional Profile

Verbasnol (Verbascoside) is a pure phytochemical compound (phenylpropanoid glycoside), not a food ingredient, and therefore has no macronutrient, micronutrient, fiber, or caloric profile in the conventional nutritional sense. Bioactive composition: Verbascoside (acteoside) is the primary and sole active molecule, with molecular formula C29H36O15 and molecular weight of 624.59 g/mol. It consists of a caffeic acid ester linked to a disaccharide backbone (3,4-dihydroxyphenylethanol-glucoside with rhamnose). Typical purity in standardized extracts ranges from 95–98% verbascoside by HPLC. Bioavailability: Oral bioavailability is notably low due to extensive hydrolysis by intestinal microbiota; gut bacteria cleave the glycoside bond, releasing hydroxytyrosol and caffeic acid as primary metabolites, which are the systemically absorbed forms. Peak plasma concentrations of metabolites appear within 1–3 hours post-ingestion. Polyphenol content: As a concentrated polyphenol, it contributes to total phenolic load when measured by Folin-Ciocalteu assay; source plants (e.g., Verbascum, Cistanche, Olea) may contain 0.1–3.5% verbascoside by dry weight. No vitamins, minerals, dietary fiber, protein, fat, or carbohydrates are present in isolated compound form. Stability: Sensitive to light, heat (>60°C), and alkaline pH, which can reduce bioactive content in formulations.

Preparation & Dosage

The only clinically studied human dosage is 100mg oral verbascoside daily for 2 weeks. Proprietary extracts are typically standardized to ≥5% verbascoside content. In vitro studies used concentrations of 0.8-16 µM for β-cell protection and up to 400 µM without cytotoxicity. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Antioxidants (vitamin C, vitamin E), Anti-inflammatory herbs (turmeric, boswellia), Neuroprotective compounds (omega-3s, resveratrol)

Safety & Interactions

Verbascoside has not been evaluated in large-scale human safety trials, so a formally established safety profile and tolerable upper intake level do not currently exist. Animal studies have not reported significant acute toxicity at physiological doses, but high-dose or long-term human safety data are lacking. Because verbascoside modulates iNOS activity and inflammatory pathways, theoretical interactions exist with NSAIDs, corticosteroids, and immunosuppressant drugs, though no confirmed clinical drug interactions have been documented. Pregnant or breastfeeding individuals and those on chronic medication should avoid supplementation until human safety data are available.